Drug intelligence / Profile preview

CardioRel

Development stage: Unknown
Lead developer: Reliance Life Sciences
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intra-arterial, Intravenous

Overview

CardioRel is an autologous cell therapy consisting of bone marrow-derived mesenchymal stem cells (and mononuclear cells) developed by Reliance Life Sciences. It is designed for early or planned intervention in patients with cardiac disorders, specifically acute myocardial infarction. The therapy aims to repair damaged myocardial tissue and improve cardiac function through mechanisms such as immunomodulation, neovascularization, and endogenous tissue repair. CardioRel has received regulatory approval in India from the Central Drugs Standard Control Organisation (CDSCO) for the treatment of myocardial infarction.

Brand names: CardioRel
Other names: autologous bone marrow derived mesenchymal stem cellsautologous bone marrow mononuclear cells and mesenchymal stem cells

Beyond the preview

Go deeper on CardioRel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CardioRel.